Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. - Wikidata - wikimedia - TriplyDB

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

http://www.wikidata.org/entity/Q36315291

about

The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy Delivery of oligonucleotides with lipid nanoparticles Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown.Lipid-Based Nanocarriers for RNA Delivery Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice mRNA vaccine delivery using lipid nanoparticles.The roles of individual mammalian argonautes in RNA interference in vivo.Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity.Next generation delivery system for proteins and genes of therapeutic purpose: why and how?Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight Epigenetic modulation in the treatment of atherosclerotic disease Light-scattering detection below the level of single fluorescent molecules for high-resolution characterization of functional nanoparticles.Oligonucleotide delivery: a patent review (2010 - 2013).Ionizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivo Identification of siRNA delivery enhancers by a chemical library screen.Combinatorial Approach to Nanoarchitectonics for Nonviral Delivery of Nucleic Acids.Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model.Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases.Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA.Intercalation-mediated nucleic acid nanoparticles for siRNA delivery.Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature.Reductively Responsive Hydrogel Nanoparticles with Uniform Size, Shape, and Tunable Composition for Systemic siRNA Delivery in Vivo.Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification.Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery.The delivery of therapeutic oligonucleotides Lipid Nanoparticle-mediated siRNA Transfer Against PCTAIRE1/PCTK1/Cdk16 Inhibits In Vivo Cancer Growth.A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo.Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system.Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles.Lipid-modified aminoglycoside derivatives for in vivo siRNA delivery.Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge.

P2860

Q26827175-9FB0EBAA-3741-4670-81EE-4AC594CF3D85 Q26992271-80C092BF-5B22-4EAB-BF36-D67B1615F3F4 Q27024646-44C3A512-8E5B-4CD4-9B4B-F1639C9D4FB9 Q27313970-E38A4DDE-0FC1-48C0-A7AA-C4D47271AAFE Q28080706-1994F587-5BEF-45C7-B626-DD893D9AD69A Q28656365-8B05598E-83A9-4B32-B541-AD2DC7DA0925 Q33694417-097D1688-F015-4FE5-B8AE-913F46AAE524 Q33711685-2C212F2C-FCFB-48FA-A7D7-A31E387984D1 Q33846059-3EC43225-4EBA-4815-995F-EB0ABD7C5B8C Q33954008-938B33D8-1B52-43F4-A737-AF317FA8A0AA Q34003800-410274F8-23F7-46B6-965D-956BCC0B9E3B Q34375398-3740E271-325A-444C-A415-2EAA9687A7EE Q34393539-CD124382-C060-4E81-9943-436BFC4B7733 Q34413965-53FD60C5-4770-48DF-A01E-918EED6FC6BA Q34419873-8451249C-42DE-4CEA-BF77-8D17BFBB9DC0 Q35163373-4F6669CA-A9AB-4D82-A718-073A5D26FDB5 Q35374908-79C9D86A-BEFF-4052-83DA-46930A5CFC60 Q35721260-5E63EC4F-CAA2-4D94-AB20-7997D9192170 Q35853451-9886937D-6799-4975-A4C6-DE02BED5144F Q35884898-F21EC759-42D8-4C4E-94D7-7E5F700CE185 Q36081720-6C28F85E-04F2-4AA2-BED7-0C160CA7F7C6 Q36130906-E98F48D9-0A89-445B-A8EE-F73372E36071 Q36134911-4C428874-E3CB-44E6-B514-9EB55C53FE87 Q36155481-34BC5E47-A993-457E-A38D-70723CB9B2EB Q36218294-B2529DA1-70C1-419F-9A2D-9E23100C0DCB Q36459323-169B04B8-FB9F-4566-AA20-30B48CC4EFC0 Q36757051-B00A9B83-E3B5-46F4-9A51-3BC2936F419A Q36781516-4A11DF80-FC58-49B9-B44C-609D5FD77B79 Q36821612-849FAF93-95B0-49F4-9149-B3EA485D82AF Q36928112-309DA681-99EB-4C42-BFE7-D414C1E45E5B Q36981555-ACAFC6FC-ADB5-4CEA-BC6C-BC9D69AA8C73 Q37088608-F08A45CC-5D3D-48F7-8A81-1BBBDE03136F Q37210936-BEA16D00-D849-4009-91D4-9367F48D260D Q37254642-DFB4D3FB-6343-4B4C-9BA7-EAA224882514 Q37258262-4B25134E-66F1-489F-9F20-14B91260DD9D Q37325079-8D7B981B-6DD1-4A2A-A341-36D099A39D35 Q37330601-229CE6B2-42A3-48C8-8939-4A9182991278 Q37489356-89EA32B2-D86F-4230-8E10-4C9F019E4648 Q37503581-220AE742-4AD0-4B96-B0AC-6F7FCFC09BB5 Q37681765-07AF9BC2-8B75-403E-8714-4FF376C0FBA2

P2860

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

http://www.wikidata.org/entity/Q36315291

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

@ast

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

@en

type

label

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

@ast

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

@en

prefLabel

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

@ast

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

@en

P1433

Q36315291-C97AEE47-64D4-49E7-A048-2B11AF606CF7

P1476

Q36315291-6B207AC9-62E4-4CA1-B795-6B4BAE0EF2D3

P2093

Q36315291-229D2980-CD15-4607-8127-F3376C2DAD58

Q36315291-28CCA08F-63ED-4F68-BF94-FBD2520D73A1

Q36315291-3F9940AB-BD2D-4C3C-B74F-A0312854F6B0

Q36315291-402CD570-FABA-4BDF-8C1D-0FDF85A7BEFC

Q36315291-5B74E4AA-FFC1-4DED-9832-F337F2C1D1B1

Q36315291-5CF18174-003C-4408-9A42-C93531A1D96D

Q36315291-64003A23-8FC5-4099-A01E-710EBC825EED

Q36315291-7A2BD8DE-8337-466A-9A48-49EEDDE186FD

Q36315291-7B96AF94-48CF-475A-A9A5-3D12FDE9AA72

Q36315291-91FAE263-8D6C-4E68-B063-8DCA2298E785

P2860

Q36315291-041BCAC3-F163-4D55-86BE-6A9662817AA4

Q36315291-0C47A05F-EDD4-4332-AABA-0818CA933F68

Q36315291-14C37169-F366-4BB1-AD5E-3DA51482C477

Q36315291-36D54A6B-BD4C-4446-BF16-9102DEBEE35C

Q36315291-47AA8F9E-675B-4264-B920-42F9687806C8

Q36315291-523CF784-6219-453B-8A60-ECABC84D273A

Q36315291-5465A35A-5776-41F6-8AE8-A68E7E2E6EF2

Q36315291-5B9871C2-26E0-4282-90EB-57957A649002

Q36315291-8BC2D245-EE6C-4FCC-87C9-52693D2CA4CD

Q36315291-9D129487-7414-4F69-A76B-AC63D46831F9

P304

Q36315291-EC0DE551-DD3E-4D6F-9E34-5AFE55E1B711

P31

Q36315291-28B41C54-F786-4407-AC33-9F004979C4C2

P356

Q36315291-A7E0BFF6-2AED-4C24-B1A0-9C49461E9604

P407

Q36315291-FDB9356B-D7FB-42B3-B2C6-CBABC51B0B36

P433

Q36315291-D098A50C-C5EA-494F-A570-A0964DCA3A18

P478

Q36315291-9DBF480A-4A31-410F-A568-87FA56E83D78

P577

Q36315291-709AA615-90C6-4462-9731-837CEC09646F

P5875

Q36315291-87B72B7F-61C0-404C-B176-60BDB958D15C

P698

Q36315291-726333DB-75DA-4EA3-A2D5-01D600FED0E2

P921

Q36315291-91190112-D826-43B0-BF44-4849ED255D3A

Q36315291-C62C94FA-39C3-46B7-85E2-C6AD68D31C12

P932

Q36315291-078E5D9F-EF97-4C32-A0E9-83B5FFD29F70

P356

P1433

Angewandte Chemie International Edition

P1476

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

@en

P2093

Akin Akinc

http://www.w3.org/2001/XMLSchema#string

Barbara L Mui

http://www.w3.org/2001/XMLSchema#string

David Butler

http://www.w3.org/2001/XMLSchema#string

Ismail M Hafez

http://www.w3.org/2001/XMLSchema#string

Jayaprakash K Narayanannair

http://www.w3.org/2001/XMLSchema#string

Jianxin Chen

http://www.w3.org/2001/XMLSchema#string

Kallanthottathil G Rajeev

http://www.w3.org/2001/XMLSchema#string

Laxman Eltepu

http://www.w3.org/2001/XMLSchema#string

Mark A Tracy

http://www.w3.org/2001/XMLSchema#string

Martin A Maier

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

pH Homeostasis of cellular organelles.

Interfering with disease: a progress report on siRNA-based therapeutics.

Nonviral delivery of synthetic siRNAs in vivo.

Knocking down barriers: advances in siRNA delivery.

Development of lipidoid-siRNA formulations for systemic delivery to the liver.

Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids.

Rational design of cationic lipids for siRNA delivery.

On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids.

Selective silencing of a mutant transthyretin allele by small interfering RNAs.

P304

8529-8533

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANIE.201203263

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229065241

http://www.w3.org/2001/XMLSchema#string

P698

22782619

http://www.w3.org/2001/XMLSchema#string

P921

P932

3470698

http://www.w3.org/2001/XMLSchema#string